SJS Investment Consulting’s BioCryst Pharmaceuticals BCRX Stock Holding History

SJS Investment Consulting’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$134	Hold	14	–	–	﹤0.01%	2074
2025 Q4	$110	Buy	+14	New	+$101	﹤0.01%	1936
2024 Q2	–	Sell	-20	Closed	-$102	–	1668
2024 Q1	$102	Buy	20 +2	+11%	+$11	﹤0.01%	1565
2023 Q4	$108	Sell	18 -7	-28%	-$41	﹤0.01%	1543
2023 Q3	$177	Buy	25 +11	+79%	+$79	﹤0.01%	1473
2023 Q2	$99	Hold	14	–	–	﹤0.01%	1514
2023 Q1	$117	Sell	14 -12	-46%	-$116	﹤0.01%	1443
2022 Q4	$298	Buy	26 +14	+117%	+$175	﹤0.01%	1345
2022 Q3	$0	Buy	+12	New	+$154	﹤0.01%	1059
2022 Q1	$0	Buy	+2	New	+$32	﹤0.01%	739

Other funds holding BCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return